aromatic-l-amino-acid decarboxylase

Carbidopa monohydrate (S(-)-Carbidopa) is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine.

Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.

Homovanillic acid (Vanillacetic acid), a dopamine metabolite, is linked to aromatic L-amino acid decarboxylase deficiency, growth hormone deficiency, celiac disease, and sepiapterin reductase deficiency.

Brocresine is an aromatic L-amino acid decarboxylase inhibitor. It has both a peripheral and central action.

Budipine is a non-dopaminergic antiparkinsonian drug. The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulatio

(4-Hydroxy-3-methoxyphenyl)acetic-2,2-d2 Acid is a deuterated compound of (4-Hydroxy-3-methoxyphenyl)acetic Acid. (4-Hydroxy-3-methoxyphenyl)acetic Acid has a CAS number of 306-08-1. Homovanillic acid is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.

Homovanillic Acid-13C-d3 the 13C and deuterated compound of Homovanillic Acid. Homovanillic Acid has a CAS number of 306-08-1. Homovanillic acid is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.

Catalpalactone exhibits high antitermitic, and cytotoxic activities, it exhibits potent inhibitory effects on lipopolysaccharide-induced NO synthesis in RAW 264.7 cells , with IC50 values of 9.80 microM. Catalpalactone can inhibit dopamine biosynthesis by